Search Results
Your search for ,WHo matches 21068 pages
Showing 4251 - 4300Living With Metastatic Breast Cancer
After my first breast cancer diagnosis, in 2010, the odds for a cure were seemingly all weighted in my favor. A routine mammogram screening had picked up a small—less than 1 cm—mass in my right breast, and a tissue biopsy confirmed it was stage I estrogen receptor–positive breast cancer. I had no...
The Development of Geriatric Oncology in France: An Outside View
With the aging of the world population, geriatric oncology is becoming a mainstay. Over the past year in The ASCO Post, we published a couple of articles on the history of oncology, including one on the history of geriatric oncology in the United States and Europe. Our goal was to promote a...
Darolutamide Combined With Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
On August 5, 2022, darolutamide was approved for use in combination with docetaxel for patients with metastatic hormone-sensitive prostate cancer.1 Approval was based on the double-blind ARASENS trial (ClinicalTrials.gov identifier NCT02799602), in which 1,305 patients were randomly assigned to...
Update on the Impact of the Russian Invasion of Ukraine on Patients With Cancer
In the more than 7 months since Russia invaded Ukraine on February 24, 2022, cancer care for Ukrainian citizens has changed dramatically. Ukraine was once a country able to provide its approximately 160,000 newly diagnosed patients with cancer each year with modern diagnostic methods, including...
Shaji K. Kumar, MD, Named Editor-in-Chief of The Hematologist
Shaji K. Kumar, MD, an expert in multiple myeloma and monoclonal gammopathies, has been appointed to the position of Editor-in-Chief of The Hematologist: ASH News and Reports, the official member news magazine of the American Society of Hematology (ASH). As the seventh Editor-in-Chief of the...
Cristina R. Ferrone, MD, Named Chair of Cedars-Sinai Department of Surgery
Following an extensive national search, Cedars-Sinai Medical Center, Los Angeles, has appointed Cristina R. Ferrone, MD, as Chair of the Department of Surgery. Currently Professor of Surgery at Harvard Medical School and Director of the Office of Clinical Careers for Massachusetts General...
Sublobar Resection for Small, Early-Stage NSCLC: Establishing a New Standard of Care?
After a nearly 20-year wait, the results are finally in: sublobar surgery has been found to be noninferior to lobectomy and may be the new standard of care of patients with small, early-stage non–small cell lung cancer (NSCLC). Results of the phase III Alliance trial, presented at the International ...
ESMO 2022: Updates in Skin Cancer
On this episode, we’re highlighting speakers who presented data in skin cancer during the ESMO Congress 2022, including findings on tumor-infiltrating lymphocyte therapy in advanced melanoma, cemiplimab in cutaneous squamous cell carcinoma, and the association of circulating tumor DNA and disease...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Health-Related Quality of Life for Survivors of Metastatic Prostate Cancer
Survivors of prostate cancer originally diagnosed with metastatic disease may experience significantly worse health-related quality of life than those diagnosed with early-stage disease and individuals without a cancer history across all domains, according to a new study by Zheng et al published in ...
Medicaid Expansion and Palliative Care Use Among Patients Newly Diagnosed With Advanced Cancer
Recent data showed that Medicaid expansion may be associated with increased use of palliative care among newly diagnosed individuals with stage IV cancer, although overall usage of palliative care was low. In addition, the increase after Medicaid expansion varied by cancer type, according to a...
Joannie M. Ivory, MD, MSPH, on Increasing Participation of Black Patients With Cancer in Clinical Trials
Joannie M. Ivory, MD, MSPH, of The University of North Carolina at Chapel Hill, discusses ways to raise the number of Black patients with cancer who take part in clinical trials. More successful accrual may be linked to conducting trials where Black patients live and designing studies to recruit a...
Chemotherapy for Children With Type II or III Pleuropulmonary Blastoma
In an analysis from the International PPB/DICER1 Registry reported in the Journal of Clinical Oncology, Schultz et al found that chemotherapy with IVADo (ifosfamide, vincristine, actinomycin-D, and doxorubicin) appeared to be associated with similar or improved outcomes vs historical controls among ...
New Study Highlights Sexual Problems Among Young Women Who Have Had Cancer
Young women who are cancer survivors may be at a much higher risk of sexual problems, including loss of libido and discomfort, according to research published by Wettergren et al in the journal Acta Oncologica. The study also suggests that cancer type and intensity of treatment may influence the...
Transportation Barriers Among Cancer Survivors: Effect on ER Use and Mortality
New research showed that cancer survivors who delayed care due to a lack of transportation were more likely to use the emergency room (ER), according to the study published by Jiang et al in the Journal of Clinical Oncology. They also had the highest risks of all-cause and cancer-specific...
Christopher E. Jensen, MD, on Older Adults With AML: A Price Paid for High-Intensity Chemotherapy?
Christopher E. Jensen, MD, of the University of North Carolina School of Medicine, talks about older adults with acute myeloid leukemia who receive high-intensity chemotherapy. Although they may live longer, much of their survival gains may be spent engaged in oncology care (Abstract 376).
GPRC5D-Targeted CAR T-Cell Therapy in Heavily Pretreated Patients With Multiple Myeloma
In a single-institution phase I study reported in The New England Journal of Medicine, Sham Mailankody, MBBS, and colleagues found that chimeric antigen receptor (CAR) T cells targeting G protein–coupled receptor, class C, group 5, member D (GPRC5D) were active in heavily pretreated patients with...
Minimally Invasive vs Open Nephrectomy for Kidney Cancer: 1-Year Health-Care Expenditure and Utilization
In a retrospective cohort study reported in JAMA Network Open, Okhawere et al found that minimally invasive surgery was associated with similar or reduced total expenditures vs open surgery during the first year after partial or radical nephrectomy for kidney cancer. Study Details The study...
Oncologist Use of Reduced Doses of New Systemic Treatments in Patients With Metastatic Cancer
In a survey study reported in JCO Oncology Practice, Jimenez et al found that half of surveyed oncologists reported sometimes or usually using reduced doses at initiation of a new systemic treatment in patients with metastatic cancer in order to potentially reduce toxicity. Study Details The study...
Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
In a single-institution study reported in JAMA Oncology, Allen S. Ho, MD, and colleagues found evidence that active surveillance may be a suitable treatment for most patients with low-risk papillary thyroid carcinoma. Study Details The prospective study included 222 patients enrolled at...
IASLC Names Co-Chairs of the 2023 World Conference on Lung Cancer
Three thoracic oncologists were named co-chairs of the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), which will take place September 9–12 in Singapore. Co-chairs work with IASLC to plan the annual research meeting, select program track...
Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Trial Findings
Concurrent chemoradiation therapy followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 However, clinical trials have predetermined inclusion and exclusion criteria, and they evaluate...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
Expert Point of View: Jacek Jassem, MD
Abstract discussant Jacek Jassem, MD, of the Medical University of Gdansk, Poland, underscored smoking as the most important cause of lung cancer, noting that between 85% and 90% of patients with lung cancer are current or former smokers. “Lung cancer screening, which has recently become standard...
Study Finds High-Intensity Intervention Helped One-Third of Participants in Lung Cancer Screening Program to Quit Smoking
Despite significant advancements in cancer therapy, the number-one stopper of lung cancer remains the most basic intervention: quitting smoking. Unfortunately, for long-term smokers, that intervention can sometimes be the most challenging. According to data presented during the International...
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were...
Highlights From the IASLC 2022 World Conference on Lung Cancer
Over the past few years, we have seen rapid and dramatic transformation in the therapeutic landscape of non–small cell lung cancer (NSCLC). We have had multiple new targeted therapies for newer targets (previously undruggable targets) and better diagnostic strategies to workup patients to realize...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, Professor in Thoracic Radiology at Royal Brompton and Harefield Hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, highlighted the increased risk of second primary tumors among current...
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
DART Trial: Concurrent Radiotherapy Plus Durvalumab Active in Older Patients With Locally Advanced Lung Cancer
Interim results of a phase II study have demonstrated the safety and feasibility of treating elderly and frail patients with locally advanced non–small cell lung cancer (NSCLC) with the monoclonal antibody durvalumab during and after radiation therapy, without chemotherapy. The results of a...
Expert Point of View: Corinne Faivre-Finn, MD, PhD, and Masahiro Tsuboi, MD
The first discussant of the NADIM II study, Corinne Faivre-Finn, MD, PhD, Professor of Thoracic Radiation Oncology, University of Manchester, and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust, Manchester, England, called the results “very impressive” but noted that...
NADIM II Trial: Neoadjuvant Chemoimmunotherapy Improved Survival in Resectable, Stage IIIA NSCLC
In patients with resectable, stage IIIA non–small cell lung cancer (NSCLC), the addition of neoadjuvant nivolumab to platinum-based chemotherapy significantly improved overall survival compared with neoadjuvant chemotherapy alone, according to data presented by Mariano Provencio, MD, PhD, at the...
Expert Point of View: Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD
Discussant of the exploratory analysis of the POSEIDON trial, Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD, a medical oncologist at Tan Tock Seng Hospital, Singapore, noted that although 30% of the mutation-evaluable population had KRAS mutations, only a small percentage of patients had co-mutated...
Highlights From the 2022 ASCO Quality Care Symposium
The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we’re featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing...
Study Focuses on Molecular Details of Precancerous Clonal Outgrowth in Blood Cells
A common, spontaneous mutation in blood stem cells, which has been linked to a higher risk of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce, according to a study co-led by...
Selpercatinib in RET Fusion–Positive Advanced NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, and colleagues, an updated analysis of the multicohort phase I/II LIBRETTO-001 trial confirmed the activity of selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The trial supported ...
Risks Associated With Sinoatrial Node Radiation Dose in Patients With Lung Cancer Receiving Definitive Chemoradiotherapy
In a Korean single-institution retrospective cohort study reported in JAMA Oncology, Kim et al found that higher sinoatrial node radiation doses were associated with an increased risk of atrial fibrillation and poorer survival in patients with limited-stage small cell lung cancer (SCLC) and locally ...
Extended-Interval vs Standard-Interval Dosing of Single-Agent Pembrolizumab
In a retrospective cohort study performed in U.S. veterans reported in JAMA Oncology, Strohbehn et al found that a minority of patients receiving singe-agent pembrolizumab for cancer received the extended-interval dosing of 400 mg every 6 weeks. Analysis of efficacy measured as the time to...
Managing the Risk of Thrombosis in Polycythemia Vera
This is Part 1 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. Stay tuned for future installments in the coming months. In this video, Dr. Prithviraj Bose and Dr. Ruben Mesa discuss how best to manage the risk of thrombosis in patients with polycythemia vera....
Tissue vs ctDNA NGS for Detecting Actionable Alterations in Patients With Advanced Cancer
A large prospective analysis, published by Bayle et al in Annals of Oncology, evaluated differences between tissue and circulating tumor DNA (ctDNA) next-generation sequencing (NGS) with a large cancer gene panel. The investigators compared the impacts of both methods in terms of molecular tumor...
Inflammatory Markers and Clinical Decline After Adjuvant Chemotherapy in Older Women With Breast Cancer
As reported in the Journal of Clinical Oncology by Ji et al, the HOPE study (Hurria Older Patients [HOPE] with Breast Cancer Study) has shown that older women categorized as robust prior to adjuvant chemotherapy are at risk for clinical decline postchemotherapy, with high baseline levels of the...
Genetic Variation May Explain Racial Disparity in Esophageal Cancer Cases
Esophageal adenocarcinoma is a type of cancer affecting the mucus-secreting glands of the lower esophagus and is the most common form of esophageal cancer. It is often preceded by Barrett’s metaplasia, a deleterious change in cells lining the esophagus. Though the cause of esophageal adenocarcinoma ...
Report Emphasizes Continued Access to Fertility Preservation Is Critical for AYAs With Cancer Following SCOTUS Decision
The Supreme Court of the United States (SCOTUS) ruling in Dobbs v Jackson overruled Roe v Wade, returning an individual’s right to access abortion services to state law. New findings led by researchers at the American Cancer Society published by Jiang et al in The Lancet Oncology showed that more...
Lasker Foundation Announces 2022 Lasker Award Winners
On September 28, the Lasker Foundation announced the winners of the 2022 Albert Lasker Basic Medical Research Award, the 2022 Lasker~DeBakey Clinical Medical Research Award, and the 2022 Lasker~Bloomberg Public Service Award. Albert Lasker Basic Medical Research Award Richard O. Hynes, PhD, of the...
Treatment of Non–Clear Cell RCC
This is Part 4 of Updates in Renal Cell Carcinoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Wenxin (Vincent) Xu, David Braun, and Bradley McGregor discuss the treatment of non–clear cell renal cell carcinoma (RCC). The...
Second-Line Therapy and Beyond in Clear Cell RCC
This is Part 2 of Updates in Renal Cell Carcinoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Wenxin (Vincent) Xu, David Braun, and Bradley McGregor discuss second-line therapy and beyond in clear cell renal cell carcinoma...
Financial Burden of High-Cost Targeted Oral Anticancer Drugs Among Medicare Patients
In a study reported in JCO Oncology Practice, Li et al identified elements of increasing financial burden associated with the use of high-cost targeted oral anticancer drugs among Medicare patients between 2011 and 2016. The study used data from the Surveillance, Epidemiology, and End Results...
Avelumab Plus Axitinib in Advanced Type B3 Thymomas and Thymic Carcinomas
In the Italian phase II CAVEATT trial reported in The Lancet Oncology, Conforti et al found that the combination of avelumab and axitinib was active in patients with unresectable or metastatic type B3 thymomas and thymic carcinomas who experienced disease progression after platinum-based...
UAMS Winthrop P. Rockefeller Cancer Institute Welcomes Pebbles Fagan, PhD, MPH, to Leadership Team
Pebbles Fagan, PhD, MPH, has assumed the role of Associate Director for Cancer Prevention and Control for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS). Dr. Fagan, an expert on tobacco-related health disparities and co-founder of the...
Genomic Testing May Aid in Identifying Patients of African Descent With High-Risk Prostate Cancer
Black patients of African descent tend to be diagnosed more frequently with prostate cancer and have higher mortality rates than patients of other races and ethnicities. Despite this substantial disparity, few prospective studies focused on maximizing the recruitment of African American patients...
